LEPU ScienTech Medical Technology (Shanghai) (2291) Fundamentals 2026 — P/E 16.9x, Revenue Analysis | SniperIQ
LEPU ScienTech Medical Technology (Shanghai) (2291) is a CN-listed Healthcare company in Medical - Devices with a market capitalization of HK$4.6B, trading at HK
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is LEPU ScienTech Medical Technology (Shanghai)'s market cap?
LEPU ScienTech Medical Technology (Shanghai) (2291) has a market capitalization of approximately HK$4.6B, trading at HK
What is LEPU ScienTech Medical Technology (Shanghai)'s P/E ratio?
LEPU ScienTech Medical Technology (Shanghai)'s trailing twelve-month P/E ratio is 16.9x, with a price-to-book (P/B) of 2.0x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is LEPU ScienTech Medical Technology (Shanghai)?
LEPU ScienTech Medical Technology (Shanghai) runs a net profit margin of 45.4%, a gross margin of 84.7%, and an operating margin of 52.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does LEPU ScienTech Medical Technology (Shanghai) generate?
LEPU ScienTech Medical Technology (Shanghai) reported revenue of ¥528M for fiscal year 2025, with net income of ¥240M and earnings per share (EPS) of 0.69. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does LEPU ScienTech Medical Technology (Shanghai) pay a dividend?
LEPU ScienTech Medical Technology (Shanghai) offers a trailing dividend yield of about 4.3%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is LEPU ScienTech Medical Technology (Shanghai) financially healthy?
LEPU ScienTech Medical Technology (Shanghai) carries a debt-to-equity ratio of 0.00x and a current ratio of 23.54x, with a market beta of -0.23. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is LEPU ScienTech Medical Technology (Shanghai) a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For LEPU ScienTech Medical Technology (Shanghai) (2291) the key facts are: market cap HK$4.6B, P/E 16.9x, revenue ¥528M, 52-week range 8.33-27.6. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track LEPU ScienTech Medical Technology (Shanghai)'s full fundamentals live
Get LEPU ScienTech Medical Technology (Shanghai)'s 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.